Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful faithfully but unsuccessfully to develop an one-time therapy, variously named Pro 140, leronlimab, along with Vyrologix.

In development of this particular treatment, CytoDyn has cast its net wide and far both geographically and in phrases of prospective indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they’ll actually be used is an open question.

While CYDY  has been dawdling, market opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of the last few shares of mine. The first CytoDyn article of mine, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire job interview which I came away with a bad impression of the company.

Irony of irony, my bad opinion of the company has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > six bagger yet still disappoints? Therein lies the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy and avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is a late Stage II clinical development mAb with demonstrated anti viral activity of HIV infected subjects. Today’s payment of $3.5 zillion transfers ownership of this expertise and associated intellectual property coming from Progenics to CytoDyn, and roughly twenty five million mg of majority drug substance…. milestone payments after commencement of a phase III clinical trial ($1.5 zillion) as well as the first brand new drug program approval ($5 million), and even royalty payments of five % of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has made this inauspicious acquisition right into a springboard for CytoDyn to acquire a sector cap > $3.5 billion. It’s done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and numerous indications, it’s this single therapies and a “broad pipeline of indications” since it puts it. I call some pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially advantageous therapy in dozens of indications.

The opening banner of its on its site (below) shows an energetic business with diverse interests albeit centered on leronlimab, several illness types, multiple publications in addition to multiple presentations.

Can all this be smoke and mirrors? That’s a question I have been asking myself with the very beginning of my interest in this company. Judging by the multiples of thousands of several comments on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I am much from alone in this particular question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely protective of the prospects of its, quick to label any negative opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *